Advanced search for publications
Enter your keywords
Switching from disposable to reusable insulin pens
This document outlines the benefits of appropriate switching from disposable to reusable insulin pens, highlighting advantages for patients, the environment, and potential cost savings. It also provides practical recommendations for implementation by medicines optimisation teams
Drugs used in Diabetes
This report looks at prescribing trends in primary care for Drugs used in Diabetes at SICBL and ICB level with particular focus on insulins, anti-diabetic drugs and diagnostic & monitoring devices. Prescribing data is weighted with QOF registers, and also uses HES data to measure prescribing outcomes. If you have any queries about the content […]
NHS Medicines Optimisation Opportunities Dashboard
At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver […]
Medicines value tracker – Metformin 1g tablets; opportunity savings realised
The purpose of the Medicines value bulletin tracker publications are to support ICBs in monitoring progress and identifying remaining potential opportunity savings, for the Medicines value opportunities already identified in the RDTC Medicines Value Bulletin series. The MVB tracker publications for Metformin 1g IR tablets cover all 7 ICBs across the North of England. Please […]
Formulary assessment – Hydrocortisone sodium phosphate 5mg/5ml, 10mg/5ml oral solutions
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies. The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The […]
Budget impact of metformin 1g immediate release tablet prescribing
The purpose of this bulletin is to highlight the rapid increase in price of metformin 1g tablets over the last year, and to raise awareness of the difference in price of metformin 1g immediate release (IR) tablets compared with 500mg IR tablets. It considers the potential budget impact to primary care of prescribing metformin 1g […]
Formulary assessment – Calcifediol soft capsules
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies. The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The […]
Formulary assessment – Fezolinetant (Veoza)
May 2025 DRAFT NICE guidance recommends that fezolinetant should not be used to treat moderate to severe vasomotor symptoms caused by menopause. This is because there is not enough evidence to determine whether fezolinetant is value for money. This formulary assessment tool will be updated once NICE’s final guidance on fezolinetant has been published. April […]
Fezolinetant for treating vasomotor symptoms associated with the menopause
A Formulary Assessment Tool is also available on this topic. Formulary Assessment Tools are pre-populated templates with space for local adaptation, to reduce duplication and support decision-making April 2025 MHRA Drug Safety Update – Fezolinetant treatment is associated with a risk of drug induced liver injury. New recommendations have been introduced to minimise this risk. […]
Social Prescribing: Evidence and Outcomes
Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees. Social prescribing has been proposed as a mechanism to improve […]